AU2001250794B2 - Kcnb: a novel potassium channel protein - Google Patents

Kcnb: a novel potassium channel protein Download PDF

Info

Publication number
AU2001250794B2
AU2001250794B2 AU2001250794A AU2001250794A AU2001250794B2 AU 2001250794 B2 AU2001250794 B2 AU 2001250794B2 AU 2001250794 A AU2001250794 A AU 2001250794A AU 2001250794 A AU2001250794 A AU 2001250794A AU 2001250794 B2 AU2001250794 B2 AU 2001250794B2
Authority
AU
Australia
Prior art keywords
polypeptide
kcnb
nucleic acid
seq
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2001250794A
Other languages
English (en)
Other versions
AU2001250794A1 (en
Inventor
David Mu
Scott Powers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of AU2001250794A1 publication Critical patent/AU2001250794A1/en
Application granted granted Critical
Publication of AU2001250794B2 publication Critical patent/AU2001250794B2/en
Assigned to AMGEN INC. reassignment AMGEN INC. Request for Assignment Assignors: TULARIK INC
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
AU2001250794A 2000-03-03 2001-03-02 Kcnb: a novel potassium channel protein Ceased AU2001250794B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18691500P 2000-03-03 2000-03-03
US60/186,915 2000-03-03
PCT/US2001/006801 WO2001066741A2 (en) 2000-03-03 2001-03-02 Kcnb: a novel potassium channel protein

Publications (2)

Publication Number Publication Date
AU2001250794A1 AU2001250794A1 (en) 2001-11-29
AU2001250794B2 true AU2001250794B2 (en) 2006-03-02

Family

ID=22686808

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2001250794A Ceased AU2001250794B2 (en) 2000-03-03 2001-03-02 Kcnb: a novel potassium channel protein
AU5079401A Pending AU5079401A (en) 2000-03-03 2001-03-02 Kcnb: a novel potassium channel protein

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU5079401A Pending AU5079401A (en) 2000-03-03 2001-03-02 Kcnb: a novel potassium channel protein

Country Status (12)

Country Link
US (2) US7462465B2 (enExample)
EP (1) EP1266003B1 (enExample)
JP (2) JP2004500825A (enExample)
CN (1) CN1426468A (enExample)
AT (1) ATE538201T1 (enExample)
AU (2) AU2001250794B2 (enExample)
CA (1) CA2401906C (enExample)
ES (1) ES2378417T3 (enExample)
IL (2) IL151564A0 (enExample)
NZ (1) NZ521205A (enExample)
WO (1) WO2001066741A2 (enExample)
ZA (1) ZA200206999B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003057846A2 (en) * 2001-12-31 2003-07-17 Algos Therapeutics, Inc. Methods and materials for modulating task-3
WO2005052586A2 (en) * 2003-11-27 2005-06-09 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with potassium channel, subfamily k, member 3 (kcnk3)
WO2005075510A1 (en) * 2004-02-04 2005-08-18 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with potassium channel, subfamily k, member 9 (kcnk9)
US12416024B2 (en) 2018-03-29 2025-09-16 Transworld Technologies Inc. Biologically enhanced oil recovery methods

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2744730B1 (fr) 1996-02-08 1998-04-17 Centre Nat Rech Scient Nouvelle famille de canaux potassium de mammifere, leur clonage et leur utilisation notamment pour le criblage de drogues
EP1051485A1 (en) 1998-01-27 2000-11-15 Smithkline Beecham Plc Trek-1 like two pore potassium channel
EP1090118A2 (en) * 1998-06-26 2001-04-11 Incyte Pharmaceuticals, Inc. Human signal peptide-containing proteins
DE69938667D1 (de) 1998-11-09 2008-06-19 Centre Nat Rech Scient Neue familie von säugetier-kaliumkanälen, ihre klonierung und ihre verwendung, besonders für das drogenscreening
WO2000053628A2 (en) * 1999-03-05 2000-09-14 Smithkline Beecham Plc Genes encoding human potassium channel proteins
US20020137202A1 (en) * 1999-12-21 2002-09-26 Catherine Burgess Novel proteins and nucleic acids encoding same
GB2373500B (en) 2000-02-04 2004-12-15 Aeomica Inc Methods and apparatus for predicting, confirming, and displaying functional information derived from genomic sequence
EP1381626A2 (en) 2000-04-06 2004-01-21 Incyte Genomics, Inc. Human transporters and ion channels
AU2001294724A1 (en) 2000-09-25 2002-04-08 Millennium Pharmaceuticals, Inc. 56115, a novel human twik potassium channel and uses therefor

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GenBank Accession AC007869 *

Also Published As

Publication number Publication date
US7462465B2 (en) 2008-12-09
CA2401906A1 (en) 2001-09-13
JP2011115169A (ja) 2011-06-16
ES2378417T3 (es) 2012-04-12
CN1426468A (zh) 2003-06-25
US20080234470A1 (en) 2008-09-25
ZA200206999B (en) 2004-05-31
ATE538201T1 (de) 2012-01-15
NZ521205A (en) 2005-09-30
AU5079401A (en) 2001-09-17
IL151564A (en) 2008-11-03
WO2001066741A9 (en) 2003-03-06
WO2001066741A2 (en) 2001-09-13
WO2001066741A3 (en) 2002-04-04
JP2004500825A (ja) 2004-01-15
EP1266003B1 (en) 2011-12-21
CA2401906C (en) 2011-07-19
IL151564A0 (en) 2003-04-10
EP1266003A2 (en) 2002-12-18
US20020102676A1 (en) 2002-08-01

Similar Documents

Publication Publication Date Title
US20080234470A1 (en) Kcnb: a novel potassium channel protein
US7141419B2 (en) Isolated nucleic acids encoding cyclic nucleotide-gated cation channel subunit 3B (CNG3B) polypeptides
AU2001250794A1 (en) KCNB: a novel potassium channel protein
US7049137B2 (en) KCNQ5, a novel potassium channel
US7244576B2 (en) Modulators of angiogenesis
US7053183B2 (en) Human cyclic nucleotide-gated cation channel polypeptide
AU768352B2 (en) BK beta subunits of SLO family potassium channels
US7084259B2 (en) G-protein coupled receptors
AU6087300A (en) Human eag2
AU2001245675A1 (en) G-protein coupled receptors
US6994968B1 (en) BK beta subunits of Slo family potassium channels
US7041494B2 (en) DNA encoding Slo2 and Slo4, potassium channel
US6635741B1 (en) G-protein coupled receptor BCA-GPCR-3
US20030044814A1 (en) PRC17: an amplified cancer gene
AU2002359802B2 (en) Novel G-protein coupled receptors
WO1999045358A2 (en) Identification and expression of human kir5.1

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: AMGEN INC.

Free format text: FORMER APPLICANT(S): TULARIK INC

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired